跳至主要内容
临床试验/JPRN-UMIN000004237
JPRN-UMIN000004237已完成2 期

Efficacy and safety of mizoribine for patients with Sjogren's syndrome in pediatric age - Mizoribine for Sjogren's syndrome in pediatric age

Graduate School of Medicine, Chiba University0 个研究点目标入组 5 人开始时间: 2010年9月19日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
5

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
10years-old 至 20years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.Patients with a history of mizoribine use 2.Patients with a white blood cell count of not more than 3,000 / mm3 3.Pregnant women or women who may become pregnant and women who wish to become pregnant during the course of the study 4.Patients who used cevimeline hydrochloride hydrate, pilocarpine hydrochloride and anetholtrithion within the 4 week period before the start of the study 5.Patients using other immunosuppressive drugs and anti-rheumatoid drugs 6.Other patients who were judged to be ineligible for the study by an attending physician

研究者

发起方
Graduate School of Medicine, Chiba University

相似试验